Clostridioides difficile Infection in Inflammatory Bowel Diseases Patients: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Peter Tang and Version 1 by Adina Andone.

Clostridioides difficile (C. difficile) represents a major health burden with substantial economic and clinical impact. Patients with inflammatory bowel diseases (IBD) were identified as a risk category for Clostridioides difficile infection (CDI). In addition to traditional risk factors for C. difficile acquisition, IBD-specific risk factors such as immunosuppression, severity and extension of the inflammatory disease were identified. C. difficile virulence factors, represented by both toxins A and B, induce the damage of the intestinal mucosa and vascular changes, and promote the inflammatory host response. Given the potential life-threatening complications, early diagnostic and therapeutic interventions are required. The screening for CDI is recommended in IBD exacerbations, and the diagnostic algorithm consists of clinical evaluation, enzyme immunoassays (EIAs) or nucleic acid amplification tests (NAATs). An increased length of hospitalization, increased colectomy rate and mortality are the consequences of concurrent CDI in IBD patients. Selection of CD strains of higher virulence, antibiotic resistance, and the increasing rate of recurrent infections make the management of CDI in IBD more challenging.

  • inflammatory bowel disease
  • Clostridioides difficile
  • ulcerative colitis
  • Crohn’s disease

1. Introduction

The healthcare burden of Clostridioides difficile infection (CDI), especially in patients with underlying chronic disorders, dictates an increased vigilance for prompt diagnosis, appropriate treatment, and prevention measures to limit the spread. The economic and clinical impact of CDI is significant. Annual costs have been estimated to exceed $1.2 billion in the United States according to various reports [1], with increased length of hospitalization and hospital costs attributed to infection [2,3,4][2][3][4].
Given the significant health impact in the United States, Clostridioides difficile (C. difficile) has been recognized as one of the three “urgent” antibiotic resistance threats by the Centers for Disease Control and Prevention (CDC) [5]. The selection of strains of higher virulence (ribotype 027, ribotype 078) [6[6][7][8][9],7,8,9], the emergence of antibiotic resistance [10], and recurrent infections are major health threats. The risk of CDI recurrence after the primary episode is 25%, and the risk for subsequent recurrences further increases [11].
Inflammatory bowel diseases (IBD) represent chronic disorders with a complex pathogenesis involving environmental risk factors, genetic susceptibility, dysregulation of immune response to altered gut microbiome, and disruption of the epithelial barrier [12]. Inflammation of the gastrointestinal tract may have an unpredictable evolution, with periods of remissions and exacerbations. Nonsteroidal anti-inflammatory drugs and antibiotic use, infections [13,14][13][14], smoking [15[15][16],16], psychological stress [17[17][18][19][20],18,19,20], high altitude journeys and flights [21] have all been described as triggers for ulcerative colitis (UC) or Crohn’s disease (CD) flare-ups. By examining the stool during IBD relapses, C. difficile toxins were detected in 5.5% to 20% of patients [22,23][22][23].
Making the distinction between symptoms related to CDI and symptoms associated with an IBD flare can be a difficult task in practice. During IBD flares, patients experience abdominal pain, bloody diarrhea, and weight loss. Similarly, watery diarrhea, abdominal cramps, dehydration, loss of appetite and weight loss, and even rectal bleeding in severe cases, are typical symptoms of CDI. According to international guidelines, patients presenting with more than three episodes of unexplained unformed stools in 24 h should be tested for CDI [24]. Therefore, patients presenting with an IBD exacerbation should be screened for C. difficile toxins [25,26,27][25][26][27].
The risk factors for C. difficile acquisition, complex disease, and for recurrence, are older age (greater than 65 years old), current or recent exposure to broad-spectrum antibiotics (broad-spectrum penicillins, fluoroquinolones, cephalosporins, clindamycin), hospitalization [28[28][29][30],29,30], comorbidities, hypoalbuminemia, renal insufficiency [31], immunosuppression [32], chemotherapy [33,34[33][34][35][36],35,36], proton pump inhibitor (PPI) usage [37[37][38],38], nasogastric tubes [39], and gastrointestinal surgery [40]. Elderly patients, patients with immunosuppression, oncology patients, solid organ transplant recipients [41], and IBD patients also represent categories susceptible to infection.

2. Epidemiology of CDI in IBD Patients

Epidemiological data prove that the incidence of CDI among IBD patients has been increasing [42,43[42][43][44],44], with negative consequences on clinical outcomes (higher hospitalization rate, requirement for colectomy, and mortality). In a retrospective cohort study by Rodemann et al., the rate of CDI approximately doubled in CD patients (9.5 to 22.3/1000 admissions) and tripled in UC patients (18.4 to 57.6/1000) over a period of seven years (1998–2004) [45]. The increasing trend of CDI rate in IBD-hospitalized patients in the USA was also demonstrated in an analysis of data from the Nationwide Inpatient Sample: a 1.4% rate of infection in 1998, increased to 2.3% in 2004, and 2.9% in 2007, respectively [44]. The infection rate among IBD patients varies in different geographic regions: 3.4% in UC patients and 5.9% in CD patients were reported in the Netherlands [46]; 8.5% in CD and 24.7% in UC were reported in Chinese patients [47]. The rate of CDI among IBD patients with an ileal pouch anal anastomosis (IPAA) varies between 10.7 and 18.3% [48,49][48][49].

3. Pathogenic Mechanisms

C. difficile is an anaerobic, spore-forming, Gram-positive bacterium, identified as a causative agent of antibiotic-associated pseudomembranous colitis [51][50]. Infection comprises a spectrum of clinical manifestations that range from asymptomatic carriage or mild symptoms to life-threatening conditions (toxic megacolon, colonic perforation) and death [52][51]. Spores are transmitted by the fecal–oral route. Acquisition of C difficile in hospitalized patients occurs by ingestion of spores from an infected patient, transmission of pathogens via contaminated hands of healthcare personnel, or from contaminated surfaces. Antibiotic use affects gut microbiota composition and creates a favorable environment for C difficile colonization. Virulence factors responsible for damage of intestinal mucosa are two monoglycosyltransferases, enterotoxin A (TcdA) and cytotoxin B (TcdB), released by CD toxigenic strains [53][52]. These two toxins are encoded by tcdA and tcdB genes, located on the 19.6 kb pathogenicity locus (PaLoc). The PaLoc contains three other genes involved in regulation of the toxin genes (tcdR, tcdC) and toxin secretion (tcdE) [54,55][53][54]. Toxin A and toxin B bind to a specific receptor on colonic epithelial cells and affect intestinal barrier integrity by disruption of epithelial tight junctions and promotion of inflammatory host responses by neutrophil recruitment and activation of pro-inflammatory cytokines [56][55]. Additionally, vascular changes caused by these toxins, with increased production of vascular endothelial growth factor A (VEGF-A) and increased colonic vascular permeability, are involved in disease pathogenesis [57][56]. Toxigenic strains may produce both toxin A and toxin B (causing the majority of CDIs), TcdB alone (A−B+strains), or TcdA alone (A+B−strains) [58,59,60,61][57][58][59][60]. Recent research proves the positive correlation between high serum levels of toxin A and the severity of CDI [62][61]. Toxemia could explain systemic clinical manifestations in severe cases of CDI [63,64][62][63]. However, since circulating anti-toxin antibodies prevent the detection of C. difficile toxins in blood, current methods used to detect serum toxins levels have a low sensitivity [65,66][64][65]. Cytokine profile could also serve as a predictive marker for CDI severity. Yu H et al. demonstrated that high serum levels of IL-2 and IL-15 are associated with severe disease and poor prognosis, while high serum levels of IL-5 and gamma interferon are encountered in less severe disease. Therefore, anti-inflammatory agents could play an important therapeutic role by controlling host response and consequently reducing intestinal injury [67][66]. A third toxin, named C difficile transferase or binary toxin CDT, also involved in disease severity, increases bacterial adherence to intestinal epithelial cells and uptake of TcdA and TcdB [68][67]. Of note, 23% of the toxigenic strains, including the hypervirulent ribotype 027 and 078, produce binary toxin [69][68]. Asymptomatic carriers of toxigenic strains represent a population reservoir that favors the spread of infection [70,71][69][70]. C. difficile carriage was reported in 8.2% of IBD outpatients in clinical remission [72][71]. It is possible that the asymptomatic carriage of non-toxigenic strains confers protection against the toxigenic ones [73][72].

4. Risk of CDI in IBD Patients

Risk factors for Clostridioides difficile acquisition in IBD patients were analyzed in various and heterogenous studies and some contradictory data were obtained. IBD-related risk factors for CDI (such as disease location, severity and disease extent, and immunosuppressive therapy) were assessed, together with traditional risk factors (age, antibiotic exposure, hospitalization, and comorbidities). IBD patients with superimposed CDI showed distinct features, compared to the general population: younger age, with no recent exposure to antibiotics, presenting more frequently with a community-acquired infection [74][73].

4.1. The Role of Traditional Risk Factors

Increasing age and comorbidities were identified as risk factors for CDI in IBD patients, similarly to the general population [45]. The predisposition of patients with IBD colitis towards C. difficile acquisition could be explained by gut microbiota disturbance [75][74], leading to impaired resistance to C. difficile, even in the absence of recent antimicrobial exposure [74][73]. The reported rate of prior antibiotic exposure as a risk factor for CDI in IBD varies: 42% of IBD patients (compared to 69% of non-IBD patients) were exposed to antibiotics within three months before CDI in one report [42], whereas no prior antibiotic therapy was identified in 39% of CDI-IBD cases in another report [76][75]. Other authors identified the recent use of antibiotics in IBD as a risk factor for both CDI and for recurrent CDI as well [77][76]. Exposure to nonsteroidal anti-inflammatory drugs within two months prior to hospital admission for IBD flare was a risk factor for CDI in a study performed by Regnault et al. [78][77]. Although CDI is mostly a healthcare-associated infection, some authors demonstrated that CDI in IBD is more frequently community-acquired [45]. Maharshak et al. identified recent hospitalization (within the prior two months) and the use of antacids as significant risk factors for CDI in IBD patients [79][78].

4.2. The Role of IBD-Related Risk Factors

The rate of CDI is higher in UC compared to CD [45], and colonic involvement represents a significant risk factor for CD acquisition (OR 3.12; 95% CI: 1.28–5.12) [76][75]. Patients with pancolitis or left-sided colitis, more than patients with limited colonic involvement, together with patients with severe forms of IBD, are at greater risk for CDI [80,81][79][80]. Safety concerns have been raised regarding IBD-specific therapy. In a retrospective study of serious bacterial infections among 10,662 IBD patients undergoing immunomodulating therapy, corticosteroid initiation, with or without concomitant immunomodulators, was associated with a threefold increased risk for CDI compared with other immunosuppressants (RR = 3.4; 1.9–6.1). No significant association was found with infliximab use. Antibiotic therapy in the previous six months was found in 57.2% of patients with CDI [82][81]. Corticosteroids and biologics (infliximab and adalimumab) were identified as risk factors for CDI in IBD patients, as well as metronidazole, hospitalizations, higher ambulatory care visits, shorter duration of IBD, and a higher number of comorbidities [83][82]. In a systematic review and meta-analysis, Balram et al. showed that biologic therapy, antibiotic use, and colonic involvement are all risk factors for CDI in IBD [84][83]. Maintenance therapy with immunomodulators (azathioprine, 6-mercaptopurine, methotrexate) was an independent risk factor for CDI in one report [76][75], whereas presence of a fistula, antibiotics (metronidazole and cephalosporins), and infliximab (particularly in combination with antibiotics) were identified as risk factors for CDI in another report [85][84].

4.3. Genetic and Immunologic Susceptibility

Additional risk factors for CDI in IBD were studied for identification of susceptible patients. Connelly et al. showed that interleukin-4 gene-associated single-nucleotide polymorphism rs2243250 was significantly associated with CDI in IBD patients [87][85]. The susceptibility for recurrent CDI can be explained by altered host humoral immunity, while high-serum anti-toxin A or anti-toxin B antibodies are protective against recurrent infections [88,89][86][87]. In older IBD patients, an impaired capacity to produce toxin-specific antibodies and memory B-cell responses could explain the increased risk for CDI [90][88].

5. Diagnosis of CDI in IBD

5.1. Clinical Assessment

Common symptoms of CDI are: new onset diarrhea, ranging from 3 loose stools to more than 10 watery stools within a 24 h period, abdominal pain, fever, dehydration, and blood in the stool. Severe complications occur in fulminant disease and can evolve to adynamic ileus, hypotension, shock, toxic megacolon, colonic perforation and peritonitis. In IBD patients who underwent total colectomy, an increased ileostomy output with associated dehydration occurs in acute enteritis caused by C. difficile, together with fever and leukocytosis [91][89]. An increasing number of stools in patients with IPAA should raise the suspicion for C. difficile pouchitis [48,49][48][49].

5.2. Laboratory Tests

Laboratory diagnosis is recommended in symptomatic patients, and consists in the detection of toxins in a liquid stool sample. The culture for toxin-producing Clostridioides difficile (toxigenic culture TC) and cell culture cytotoxicity neutralization assay (CCNA) are methods with the highest sensitivity, but these require time and are expensive [92,93][90][91]. Compared to these methods, enzyme immunoassay (EIA) for toxins has the advantage of a rapid and easy-to-perform test, but with poor sensitivity [94][92]. Nucleic acid amplification tests (NAATs) represent sensitive methods to detect the presence of CD toxins genes. However, NAAT alone cannot make the distinction between colonization and infection and may lead to overdiagnosis and unnecessary treatment of asymptomatic carriers [95,96][93][94]. The glutamate dehydrogenase (GDH) test is a useful screening test that detects the enzyme GDH, expressed by toxigenic and non-toxigenic CD strains [97][95]. Additional laboratory tests are white blood cell count, serum albumin, creatinine, and electrolytes. Leukocytosis (>15,000 cells/mL) and increased serum creatinine level (>1.5 mg/dL) are markers of severe CDI. Patients with low albumin levels are at a higher risk of developing severe infection and recurrent CDI [98,99][96][97]. A new serological assay has been proposed to predict the risk for recurrent infection: an ELISA test measuring serum levels of toxin-A- and -B-specific antibodies, potentially identifying those patients with low levels of antibodies who are more susceptible to recurrence. However, extended research is needed to evaluate the applicability of this assay in current practice [100][98].

5.3. Diagnostic Algorithm

The diagnostic algorithm for CDI consists in EIA for GDH detection or NAAT, followed by EIA testing for toxins of the stool sample. Another approach is to test the stool sample simultaneously for GDH and free toxins (EIA), followed by NAAT or TC. According to the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), the Infectious Diseases Society of America (IDSA), and the Society for Healthcare Epidemiology of America (SHEA) guidelines, a combination of diagnostic tests is recommended [24,101][24][99]. Clinical judgement is advocated in making the distinction between colonization versus infection in PCR positives/toxins negative cases [101][99]. This approach prevents unnecessary antibiotic use that may cause disruption of normal gut microbiota and selection of vancomycin-resistant enterococcus species [102,103][100][101]. A positive GDH test with a negative EIA test for toxins demands immediate treatment in selected cases with severe symptoms and a high index of suspicion for CDI in IBD patients [104][102].

5.4. Endoscopic and Histopathological Evaluation

The classic morphologic features of CDI, consisting in the detection of inflammatory pseudomembranes on endoscopic and histological evaluation, are generally not found in IBD patients. Pseudomembranes represent a layer of fibrin, necrotic epithelial cells, mucus, leukocytes, that create the typical endoscopic appearance of elevated whitish or yellowish plaques on the colonic mucosal surface [76,105][75][103]. It is speculated that an altered mucosal inflammatory response in active IBD, or as a result of immunomodulator use, may result in the inability to form pseudomembranes [106][104]. A lower gastrointestinal endoscopy with biopsies is useful to rule out other potential causes of diarrhea, such as cytomegalovirus colitis, ischemic colitis or amoebiasis [107][105], and to evaluate the extension and the severity of IBD.

5.5. Imagistic Evaluation

Radiologic evaluation (abdominal X rays and computed tomography CT) represents an effective diagnostic method in severe, complicated cases, by detecting loss of haustration, dilated transverse or right colon in toxic megacolon, air-fluid levels, or free intraperitoneal gas in perforation. Imaging provides clues in severe colonic inflammation: bowel wall thickening, thumbprinting, accordion sign, pericolonic stranding and ascites [108,109,110][106][107][108]. Similar findings, consisting of small bowel dilatation, wall thickening, and ascites, have been described in CD enteritis [111,112][109][110]. Abdominal ultrasound allows the assessment of disease extent and severity, and specific features for both CDI and IBD can be detected: thickening of the bowel wall, colonic dehaustration, free fluid between bowel loops, colonic dilatation, or free air in complicated cases.

References

  1. Kwon, J.H.; Olsen, M.A.; Dubberke, E.R. The Morbidity, Mortality, and Costs Associated with Clostridium Difficile Infection. Infect. Dis. Clin. N. Am. 2015, 29, 123–134.
  2. Dubberke, E.R.; Olsen, M.A. Burden of Clostridium Difficile on the Healthcare System. Clin. Infect. Dis. 2012, 55 (Suppl. S2), S88–S92.
  3. Ananthakrishnan, A.N.; McGinley, E.L.; Binion, D.G. Excess Hospitalisation Burden Associated with Clostridium Difficile in Patients with Inflammatory Bowel Disease. Gut 2008, 57, 205–210.
  4. Kyne, L.; Hamel, M.B.; Polavaram, R.; Kelly, C.P. Health Care Costs and Mortality Associated with Nosocomial Diarrhea Due to Clostridium Difficile. Clin. Infect. Dis. 2002, 34, 346–353.
  5. Hampton, T. Report Reveals Scope of US Antibiotic Resistance Threat. JAMA 2013, 310, 1661.
  6. Fatima, R.; Aziz, M. The Hypervirulent Strain of Clostridium Difficile: NAP1/B1/027—A Brief Overview. Cureus 2019, 11, e3977.
  7. Giancola, S.E.; Williams, R.J.; Gentry, C.A. Prevalence of the Clostridium Difficile BI/NAP1/027 Strain across the United States Veterans Health Administration. Clin. Microbiol. Infect. 2018, 24, 877–881.
  8. Pituch, H.; Obuch-Woszczatyński, P.; Lachowicz, D.; Kuthan, R.; Dzierżanowska-Fangrat, K.; Mikucka, A.; Jermakow, K.; Pituch-Zdanowska, A.; Davies, K. Prevalence of Clostridium Difficile Infection in Hospitalized Patients with Diarrhoea: Results of a Polish Multicenter, Prospective, Biannual Point-Prevalence Study. Adv. Med. Sci. 2018, 63, 290–295.
  9. Goorhuis, A.; Bakker, D.; Corver, J.; Debast, S.B.; Harmanus, C.; Notermans, D.W.; Bergwerff, A.A.; Dekker, F.W.; Kuijper, E.J. Emergence of Clostridium Difficile Infection Due to a New Hypervirulent Strain, Polymerase Chain Reaction Ribotype 078. Clin. Infect. Dis. 2008, 47, 1162–1170.
  10. Martínez-Meléndez, A.; Tijerina-Rodríguez, L.; Morfin-Otero, R.; Camacho-Ortíz, A.; Villarreal-Treviño, L.; Sánchez-Alanís, H.; Rodríguez-Noriega, E.; Baines, S.D.; Flores-Treviño, S.; Maldonado-Garza, H.J.; et al. Circulation of Highly Drug-Resistant Clostridium Difficile Ribotypes 027 and 001 in Two Tertiary-Care Hospitals in Mexico. Microb. Drug Resist. 2018, 24, 386–392.
  11. Sheitoyan-Pesant, C.; Abou Chakra, C.N.; Pépin, J.; Marcil-Héguy, A.; Nault, V.; Valiquette, L. Clinical and Healthcare Burden of Multiple Recurrences of Clostridium Difficile Infection. Clin. Infect. Dis. 2016, 62, 574–580.
  12. De Souza, H.S.P.; Fiocchi, C.; Iliopoulos, D. The IBD Interactome: An Integrated View of Aetiology, Pathogenesis and Therapy. Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 739–749.
  13. Singh, S.; Graff, L.A.; Bernstein, C.N. Do NSAIDs, Antibiotics, Infections, or Stress Trigger Flares in IBD? Am. J. Gastroenterol. 2009, 104, 1298–1313.
  14. Theochari, N.A.; Stefanopoulos, A.; Mylonas, K.S.; Economopoulos, K.P. Antibiotics Exposure and Risk of Inflammatory Bowel Disease: A Systematic Review. Scand. J. Gastroenterol. 2018, 53, 1–7.
  15. Cosnes, J.; Carbonnel, F.; Carrat, F.; Beaugerie, L.; Cattan, S.; Gendre, J. Effects of Current and Former Cigarette Smoking on the Clinical Course of Crohn’s Disease: Smoking and Crohn’s Disease. Aliment. Pharmacol. Ther. 1999, 13, 1403–1411.
  16. Cosnes, J. What Is the Link between the Use of Tobacco and IBD? Inflamm. Bowel Dis. 2008, 14, S14–S15.
  17. Bitton, A.; Dobkin, P.L.; Edwardes, M.D.; Sewitch, M.J.; Meddings, J.B.; Rawal, S.; Cohen, A.; Vermeire, S.; Dufresne, L.; Franchimont, D.; et al. Predicting Relapse in Crohn’s Disease: A Biopsychosocial Model. Gut 2008, 57, 1386–1392.
  18. Bernstein, C.N.; Singh, S.; Graff, L.A.; Walker, J.R.; Miller, N.; Cheang, M. A Prospective Population-Based Study of Triggers of Symptomatic Flares in IBD. Am. J. Gastroenterol. 2010, 105, 1994–2002.
  19. Ananthakrishnan, A.N.; Gainer, V.S.; Perez, R.G.; Cai, T.; Cheng, S.-C.; Savova, G.; Chen, P.; Szolovits, P.; Xia, Z.; De Jager, P.L.; et al. Psychiatric Co-Morbidity Is Associated with Increased Risk of Surgery in Crohn’s Disease. Aliment. Pharmacol. Ther. 2013, 37, 445–454.
  20. Ananthakrishnan, A.N. Environmental Risk Factors for Inflammatory Bowel Disease. Gastroenterol. Hepatol. 2013, 9, 367–374.
  21. Vavricka, S.R.; Rogler, G.; Maetzler, S.; Misselwitz, B.; Safroneeva, E.; Frei, P.; Manser, C.N.; Biedermann, L.; Fried, M.; Higgins, P.; et al. High Altitude Journeys and Flights Are Associated with an Increased Risk of Flares in Inflammatory Bowel Disease Patients. J. Crohns Colitis 2014, 8, 191–199.
  22. Mylonaki, M.; Langmead, L.; Pantes, A.; Johnson, F.; Rampton, D.S. Enteric Infection in Relapse of Inflammatory Bowel Disease: Importance of Microbiological Examination of Stool. Eur. J. Gastroenterol. Hepatol. 2004, 16, 775–778.
  23. Meyer, A.M.; Ramzan, N.N.; Loftus, E.V.; Heigh, R.I.; Leighton, J.A. The Diagnostic Yield of Stool Pathogen Studies During Relapses of Inflammatory Bowel Disease. J. Clin. Gastroenterol. 2004, 38, 772–775.
  24. McDonald, L.C.; Gerding, D.N.; Johnson, S.; Bakken, J.S.; Carroll, K.C.; Coffin, S.E.; Dubberke, E.R.; Garey, K.W.; Gould, C.V.; Kelly, C.; et al. Clinical Practice Guidelines for Clostridium Difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis. 2018, 66, 987–994.
  25. Bernstein, C.N.; Fried, M.; Krabshuis, J.H.; Cohen, H.; Eliakim, R.; Fedail, S.; Gearry, R.; Goh, K.L.; Hamid, S.; Khan, A.G.; et al. World Gastroenterology Organization Practice Guidelines for the Diagnosis and Management of IBD in 2010. Inflamm. Bowel Dis. 2010, 16, 112–124.
  26. Mowat, C.; Cole, A.; Windsor, A.; Ahmad, T.; Arnott, I.; Driscoll, R.; Mitton, S.; Orchard, T.; Rutter, M.; Younge, L.; et al. Guidelines for the Management of Inflammatory Bowel Disease in Adults. Gut 2011, 60, 571–607.
  27. Surawicz, C.M.; Brandt, L.J.; Binion, D.G.; Ananthakrishnan, A.N.; Curry, S.R.; Gilligan, P.H.; McFarland, L.V.; Mellow, M.; Zuckerbraun, B.S. Guidelines for Diagnosis, Treatment, and Prevention of Clostridium Difficile Infections. Am. J. Gastroenterol. 2013, 108, 478–498.
  28. Davies, K.; Lawrence, J.; Berry, C.; Davis, G.; Yu, H.; Cai, B.; Gonzalez, E.; Prantner, I.; Kurcz, A.; Macovei, I.; et al. Risk Factors for Primary Clostridium Difficile Infection; Results From the Observational Study of Risk Factors for Clostridium Difficile Infection in Hospitalized Patients With Infective Diarrhea (ORCHID). Front. Public Health 2020, 8, 293.
  29. Wistrom, J. Frequency of Antibiotic-Associated Diarrhoea in 2462 Antibiotic-Treated Hospitalized Patients: A Prospective Study. J. Antimicrob. Chemother. 2001, 47, 43–50.
  30. McFarland, L.V.; Mulligan, M.E.; Kwok, R.Y.Y.; Stamm, W.E. Nosocomial Acquisition of Clostridium Difficile Infection. N. Engl. J. Med. 1989, 320, 204–210.
  31. Abou Chakra, C.N.; Pepin, J.; Sirard, S.; Valiquette, L. Risk Factors for Recurrence, Complications and Mortality in Clostridium Difficile Infection: A Systematic Review. PLoS ONE 2014, 9, e98400.
  32. Sanchez, T.H.; Brooks, J.T.; Sullivan, P.S.; Juhasz, M.; Mintz, E.; Dworkin, M.S.; Jones, J.L.; Adult/Adolescent Spectrum of HIV Disease Study Group. Bacterial Diarrhea in Persons with HIV Infection, United States, 1992–2002. Clin. Infect. Dis. 2005, 41, 1621–1627.
  33. Anand, A.; Glatt, A.E. Clostridium Difficile Infection Associated with Antineoplastic Chemotherapy: A Review. Clin. Infect. Dis. 1993, 17, 109–113.
  34. Chamorro, R.M.; Blanch, R.S.; Vidal, M.J.M.; España, M.A.G.; Pérez, M.J.R.; de la Haba Rodríguez, J.R.; Aguilar, E.A. Pseudomembranous Colitis Associated with Chemotherapy with 5-Fluorouracil. Clin. Transl. Oncol. 2005, 7, 258–261.
  35. Bilgrami, S.; Feingold, J.; Dorsky, D.; Edwards, R.; Bona, R.; Khan, A.; Rodriguez-Pinero, F.; Clive, J.; Tutschka, P. Incidence and Outcome of Clostridium Difficile Infection Following Autologous Peripheral Blood Stem Cell Transplantation. Bone Marrow Transplant. 1999, 23, 1039–1042.
  36. Gorschlüter, M.; Glasmacher, A.; Hahn, C.; Schakowski, F.; Ziske, C.; Molitor, E.; Marklein, G.; Sauerbruch, T.; Schmidt-Wolf, I.G.H. Clostridium Difficile Infection in Patients with Neutropenia. Clin. Infect. Dis. 2001, 33, 786–791.
  37. Janarthanan, S.; Ditah, I.; Adler, D.G.; Ehrinpreis, M.N. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: A meta-analysis. Am. J. Gastroenterol. 2012, 107, 1001–1010.
  38. Kwok, C.S.; Arthur, A.K.; Anibueze, C.I.; Singh, S.; Cavallazzi, R.; Loke, Y.K. Risk of Clostridium Difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis. Am. J. Gastroenterol. 2012, 107, 1011–1019.
  39. Bliss, D.Z. Acquisition of Clostridium Difficile-Associated Diarrhea in Hospitalized Patients Receiving Tube Feeding. Ann. Intern. Med. 1998, 129, 1012–1019.
  40. Thibault, A.; Miller, M.A.; Gaese, C. Risk Factors for the Development of Clostridium Difficile -Associated Diarrhea During a Hospital Outbreak. Infect. Control Hosp. Epidemiol. 1991, 12, 345–348.
  41. Paudel, S.; Zacharioudakis, I.M.; Zervou, F.N.; Ziakas, P.D.; Mylonakis, E. Prevalence of Clostridium Difficile Infection among Solid Organ Transplant Recipients: A Meta-Analysis of Published Studies. PLoS ONE 2015, 10, e0124483.
  42. Bossuyt, P.; Verhaegen, J.; Van Assche, G.; Rutgeerts, P.; Vermeire, S. Increasing Incidence of Clostridium Difficile-Associated Diarrhea in Inflammatory Bowel Disease. J. Crohns Colitis 2009, 3, 4–7.
  43. Jen, M.-H.; Saxena, S.; Bottle, A.; Aylin, P.; Pollok, R.C.G. Increased Health Burden Associated with Clostridium Difficile Diarrhoea in Patients with Inflammatory Bowel Disease: Healthcare Burden of C. difficile Infection in Patients with IBD. Aliment. Pharmacol. Ther. 2011, 33, 1322–1331.
  44. Ananthakrishnan, A.N.; McGinley, E.L.; Saeian, K.; Binion, D.G. Temporal Trends in Disease Outcomes Related to Clostridium Difficile Infection in Patients with Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2011, 17, 976–983.
  45. Rodemann, J.F.; Dubberke, E.R.; Reske, K.A.; Seo, D.H.; Stone, C.D. Incidence of Clostridium Difficile Infection in Inflammatory Bowel Disease. Clin. Gastroenterol. Hepatol. 2007, 5, 339–344.
  46. Masclee, G.M.C.; Penders, J.; Jonkers, D.M.A.E.; Wolffs, P.F.G.; Pierik, M.J. Is Clostridium Difficile Associated With Relapse of Inflammatory Bowel Disease? Results From a Retrospective and Prospective Cohort Study in the Netherlands. Inflamm. Bowel Dis. 2013, 19, 2125–2131.
  47. Chen, X.L.; Deng, J.; Chen, X.; Wan, S.S.; Wang, Y.; Cao, Q. High incidence and morbidity of Clostridium difficile infection among hospitalized patients with inflammatory bowel disease: A prospective observational cohort study. J. Dig. Dis. 2019, 20, 460–466.
  48. Li, Y.; Qian, J.; Queener, E.; Shen, B. Risk Factors and Outcome of PCR-Detected Clostridium Difficile Infection in Ileal Pouch Patients. Inflamm. Bowel Dis. 2013, 19, 397–403.
  49. Shen, B.; Jiang, Z.; Fazio, V.; Remzi, F.; Rodriguez, L.; Bennett, A.; Lopez, R.; Queener, E.; Dupont, H. Clostridium Difficile Infection in Patients With Ileal Pouch–Anal Anastomosis. Clin. Gastroenterol. Hepatol. 2008, 6, 782–788.
  50. Bartlett, J.G.; Moon, N.; Chang, T.W.; Taylor, N.; Onderdonk, A.B. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology 1978, 75, 778–782.
  51. Rupnik, M.; Wilcox, M.H.; Gerding, D.N. Clostridium Difficile Infection: New Developments in Epidemiology and Pathogenesis. Nat. Rev. Microbiol. 2009, 7, 526–536.
  52. Kuehne, S.A.; Cartman, S.T.; Heap, J.T.; Kelly, M.L.; Cockayne, A.; Minton, N.P. The Role of Toxin A and Toxin B in Clostridium Difficile Infection. Nature 2010, 467, 711–713.
  53. Govind, R.; Dupuy, B. Secretion of Clostridium Difficile Toxins A and B Requires the Holin-like Protein TcdE. PLoS Pathog. 2012, 8, e1002727.
  54. Martin-Verstraete, I.; Peltier, J.; Dupuy, B. The Regulatory Networks That Control Clostridium Difficile Toxin Synthesis. Toxins 2016, 8, 153.
  55. Kelly, C.P.; Kyne, L. The Host Immune Response to Clostridium Difficile. J. Med. Microbiol. 2011, 60, 1070–1079.
  56. Huang, J.; Kelly, C.P.; Bakirtzi, K.; Villafuerte Gálvez, J.A.; Lyras, D.; Mileto, S.J.; Larcombe, S.; Xu, H.; Yang, X.; Shields, K.S.; et al. Clostridium Difficile Toxins Induce VEGF-A and Vascular Permeability to Promote Disease Pathogenesis. Nat. Microbiol. 2019, 4, 269–279.
  57. Drudy, D.; Harnedy, N.; Fanning, S.; O’Mahony, R.; Kyne, L. Isolation and Characterisation of Toxin A-Negative, Toxin B-Positive Clostridium Difficile in Dublin, Ireland. Clin. Microbiol. Infect. 2007, 13, 298–304.
  58. Johnson, S.; Kent, S.A.; O’Leary, K.J.; Merrigan, M.M.; Sambol, S.P.; Peterson, L.R.; Gerding, D.N. Fatal Pseudomembranous Colitis Associated with a Variant Clostridium difficile Strain Not Detected by Toxin A Immunoassay. Ann. Intern. Med. 2001, 135, 434–438.
  59. Marvaud, J.-C.; Quevedo-Torres, S.; Eckert, C.; Janoir, C.; Barbut, F. Virulence of New Variant Strains of Clostridium Difficile Producing Only Toxin A or Binary Toxin in the Hamster Model. New Microbes New Infect. 2019, 32, 100590.
  60. Samra, Z.; Talmor, S.; Bahar, J. High Prevalence of Toxin A-Negative Toxin B-Positive Clostridium Difficile in Hospitalized Patients with Gastrointestinal Disease. Diagn. Microbiol. Infect. Dis. 2002, 43, 189–192.
  61. Granata, G.; Mariotti, D.; Ascenzi, P.; Petrosillo, N.; di Masi, A. High Serum Levels of Toxin A Correlate with Disease Severity in Patients with Clostridioides difficile Infection. Antibiotics 2021, 10, 1093.
  62. Di Bella, S.; Ascenzi, P.; Siarakas, S.; Petrosillo, N.; di Masi, A. Clostridium Difficile Toxins A and B: Insights into Pathogenic Properties and Extraintestinal Effects. Toxins 2016, 8, 134.
  63. Steele, J.; Chen, K.; Sun, X.; Zhang, Y.; Wang, H.; Tzipori, S.; Feng, H. Systemic Dissemination of Clostridium Difficile Toxins A and B Is Associated With Severe, Fatal Disease in Animal Models. J. Infect. Dis. 2012, 205, 384–391.
  64. Yu, H.; Chen, K.; Wu, J.; Yang, Z.; Shi, L.; Barlow, L.L.; Aronoff, D.M.; Garey, K.W.; Savidge, T.C.; von Rosenvinge, E.C.; et al. Identification of Toxemia in Patients with Clostridium Difficile Infection. PLoS ONE 2015, 10, e0124235.
  65. Sprague, R.; Warny, K.; Pollock, N.; Daugherty, K.; Lin, Q.; Xu, H.; Cuddemi, C.; Barrett, C.; Chen, X.; Banz, A.; et al. Absence of Toxemia in Clostridioides difficile Infection: Results from Ultrasensitive Toxin Assay of Serum. Dig. Dis. Sci. 2021, 66, 3303–3306.
  66. Yu, H.; Chen, K.; Sun, Y.; Carter, M.; Garey, K.W.; Savidge, T.C.; Devaraj, S.; Tessier, M.E.; von Rosenvinge, E.C.; Kelly, C.P.; et al. Cytokines Are Markers of the Clostridium Difficile-Induced Inflammatory Response and Predict Disease Severity. Clin. Vaccine Immunol. 2017, 24, e00037-17.
  67. Gerding, D.N.; Johnson, S.; Rupnik, M.; Aktories, K. Clostridium Difficile Binary Toxin CDT: Mechanism, Epidemiology, and Potential Clinical Importance. Gut Microbes 2014, 5, 15–27.
  68. Bauer, M.P.; Notermans, D.W.; van Benthem, B.H.; Brazier, J.S.; Wilcox, M.H.; Rupnik, M.; Monnet, D.L.; van Dissel, J.T.; Kuijper, E.J. Clostridium Difficile Infection in Europe: A Hospital-Based Survey. Lancet 2011, 377, 63–73.
  69. Furuya-Kanamori, L.; Marquess, J.; Yakob, L.; Riley, T.V.; Paterson, D.L.; Foster, N.F.; Huber, C.A.; Clements, A.C.A. Asymptomatic Clostridium Difficile Colonization: Epidemiology and Clinical Implications. BMC Infect. Dis. 2015, 15, 516.
  70. Crobach, M.J.T.; Vernon, J.J.; Loo, V.G.; Kong, L.Y.; Péchiné, S.; Wilcox, M.H.; Kuijper, E.J. Understanding Clostridium Difficile Colonization. Clin. Microbiol. Rev. 2018, 31, e00021-17.
  71. Clayton, E.M.; Rea, M.C.; Shanahan, F.; Quigley, E.M.M.; Kiely, B.; Hill, C.; Ross, R.P. The Vexed Relationship Between Clostridium Difficile and Inflammatory Bowel Disease: An Assessment of Carriage in an Outpatient Setting Among Patients in Remission. Am. J. Gastroenterol. 2009, 104, 1162–1169.
  72. Riley, T.V.; Collins, D.A.; Karunakaran, R.; Kahar, M.A.; Adnan, A.; Hassan, S.A.; Zainul, N.H.; Rustam, F.R.M.; Wahab, Z.A.; Ramli, R.; et al. High Prevalence of Toxigenic and Nontoxigenic Clostridium Difficile Strains in Malaysia. J. Clin. Microbiol. 2018, 56, e00170-18.
  73. Khanna, S.; Shin, A.; Kelly, C.P. Management of Clostridium Difficile Infection in Inflammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute. Clin. Gastroenterol. Hepatol. 2017, 15, 166–174.
  74. Machiels, K.; Joossens, M.; Sabino, J.; De Preter, V.; Arijs, I.; Eeckhaut, V.; Ballet, V.; Claes, K.; Van Immerseel, F.; Verbeke, K.; et al. A Decrease of the Butyrate-Producing Species Roseburia Hominis and Faecalibacterium Prausnitzii Defines Dysbiosis in Patients with Ulcerative Colitis. Gut 2014, 63, 1275–1283.
  75. Issa, M.; Vijayapal, A.; Graham, M.B.; Beaulieu, D.B.; Otterson, M.F.; Lundeen, S.; Skaros, S.; Weber, L.R.; Komorowski, R.A.; Knox, J.F.; et al. Impact of Clostridium Difficile on Inflammatory Bowel Disease. Clin. Gastroenterol. Hepatol. 2007, 5, 345–351.
  76. Kariv, R.; Navaneethan, U.; Venkatesh, P.G.K.; Lopez, R.; Shen, B. Impact of Clostridium Difficile Infection in Patients with Ulcerative Colitis. J. Crohns Colitis 2011, 5, 34–40.
  77. Regnault, H.; Bourrier, A.; Lalande, V.; Nion-Larmurier, I.; Sokol, H.; Seksik, P.; Barbut, F.; Cosnes, J.; Beaugerie, L. Prevalence and risk factors of Clostridium difficile infection in patients hospitalized for flare of inflammatory bowel disease: A retrospective assessment. Dig. Liver Dis. 2014, 46, 1086–1092.
  78. Maharshak, N.; Barzilay, I.; Zinger, H.; Hod, K.; Dotan, I. Clostridium Difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease: Prevalence, Risk Factors, and Prognosis. Medicine 2018, 97, e9772.
  79. Powell, N.; Jung, S.E.; Krishnan, B. Clostridium difficile infection and inflammatory bowel disease: A marker for disease extent? Gut 2008, 57, 1183–1184.
  80. Pascarella, F.; Martinelli, M.; Miele, E.; Del Pezzo, M.; Roscetto, E.; Staiano, A. Impact of Clostridium Difficile Infection on Pediatric Inflammatory Bowel Disease. J. Pediatr. 2009, 154, 854–858.
  81. Schneeweiss, S.; Korzenik, J.; Solomon, D.H.; Canning, C.; Lee, J.; Bressler, B. Infliximab and Other Immunomodulating Drugs in Patients with Inflammatory Bowel Disease and the Risk of Serious Bacterial Infections. Aliment. Pharmacol. Ther. 2009, 30, 253–264.
  82. Singh, H.; Nugent, Z.; Yu, B.N.; Lix, L.M.; Targownik, L.E.; Bernstein, C.N. Higher Incidence of Clostridium Difficile Infection Among Individuals With Inflammatory Bowel Disease. Gastroenterology 2017, 153, 430–438.e2.
  83. Balram, B.; Battat, R.; Al-Khoury, A.; D’Aoust, J.; Afif, W.; Bitton, A.; Lakatos, P.L.; Bessissow, T. Risk Factors Associated with Clostridium Difficile Infection in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J. Crohns Colitis 2019, 13, 27–38.
  84. Zhang, T.; Lin, Q.-Y.; Fei, J.-X.; Zhang, Y.; Lin, M.-Y.; Jiang, S.-H.; Wang, P.; Chen, Y. Clostridium Difficile Infection Worsen Outcome of Hospitalized Patients with Inflammatory Bowel Disease. Sci. Rep. 2016, 6, 29791.
  85. Connelly, T.M.; Koltun, W.A.; Sangster, W.; Berg, A.S.; Hegarty, J.P.; Harris, L.; Deiling, S.; Stewart, D.B. An Interleukin-4 Polymorphism Is Associated with Susceptibility to Clostridium Difficile Infection in Patients with Inflammatory Bowel Disease: Results of a Retrospective Cohort Study. Surgery 2014, 156, 769–775.
  86. Kyne, L.; Warny, M.; Qamar, A.; Kelly, C.P. Association between Antibody Response to Toxin A and Protection against Recurrent Clostridium Difficile Diarrhoea. Lancet 2001, 357, 189–193.
  87. Gupta, S.B.; Mehta, V.; Dubberke, E.R.; Zhao, X.; Dorr, M.B.; Guris, D.; Molrine, D.; Leney, M.; Miller, M.; Dupin, M.; et al. Antibodies to Toxin B Are Protective Against Clostridium Difficile Infection Recurrence. Clin. Infect. Dis. 2016, 63, 730–734.
  88. Monaghan, T.M.; Robins, A.; Knox, A.; Sewell, H.F.; Mahida, Y.R. Circulating Antibody and Memory B-Cell Responses to C. difficile Toxins A and B in Patients with C. difficile-Associated Diarrhoea, Inflammatory Bowel Disease and Cystic Fibrosis. PLoS ONE 2013, 8, e74452.
  89. Navaneethan, U.; Giannella, R.A. Thinking beyond the Colon-Small Bowel Involvement in Clostridium Difficile Infection. Gut Pathog. 2009, 1, 7.
  90. Senok, A.C.; Aldosari, K.M.; Alowaisheq, R.A.; Abid, O.A.; Alsuhaibani, K.A.; Khan, M.A.; Somily, A.M. Detection of Clostridium difficile antigen and toxin in stool specimens: Comparison of the C. difficile quik chek complete enzyme immunoassay and GeneXpert C. difficile polymerase chain reaction assay. Saudi J. Gastroenterol. 2017, 23, 259–262.
  91. Humphries, R.M.; Uslan, D.Z.; Rubin, Z. Performance of Clostridium Difficile Toxin Enzyme Immunoassay and Nucleic Acid Amplification Tests Stratified by Patient Disease Severity. J. Clin. Microbiol. 2013, 51, 869–873.
  92. Boyanton, B.L., Jr.; Sural, P.; Loomis, C.R.; Pesta, C.; Gonzalez-Krellwitz, L.; Robinson-Dunn, B.; Riska, P. Loop-mediated isothermal amplification compared to real-time PCR and enzyme immunoassay for toxigenic Clostridium difficile detection. J. Clin. Microbiol. 2012, 50, 640–645.
  93. Polage, C.R.; Gyorke, C.E.; Kennedy, M.A.; Leslie, J.L.; Chin, D.L.; Wang, S.; Nguyen, H.H.; Huang, B.; Tang, Y.-W.; Lee, L.W.; et al. Overdiagnosis of Clostridium Difficile Infection in the Molecular Test Era. JAMA Intern. Med. 2015, 175, 1792–1801.
  94. Zou, J.; Leung, V.; Champagne, S.; Hinch, M.; Wong, A.; Lloyd-Smith, E.; Nguyen, T.T.; Romney, M.G.; Sharma, A.; Payne, M.; et al. Clinical heterogeneity of patients with stool samples testing PCR/Tox- from a two-step Clostridium difficile diagnostic algorithm. Eur. J. Clin. Microbiol. Infect. Dis. 2018, 37, 2355–2359.
  95. Gateau, C.; Couturier, J.; Coia, J.; Barbut, F. How to: Diagnose Infection Caused by Clostridium Difficile. Clin. Microbiol. Infect. 2018, 24, 463–468.
  96. Di Bella, S.; di Masi, A.; Turla, S.; Ascenzi, P.; Gouliouris, T.; Petrosillo, N. The Protective Role of Albumin in Clostridium Difficile Infection: A Step Toward Solving the Puzzle. Infect. Control Hosp. Epidemiol. 2015, 36, 1478–1480.
  97. Kumarappa, V.S.; Patel, H.; Shah, A.; Baddoura, W.; DeBari, V.A. Temporal changes in serum albumin and total protein in patients with hospital-acquired Clostridium difficile infection. Ann. Clin. Lab. Sci. 2014, 44, 32–37.
  98. Von Bechtolsheim, F.; Varga, A.; Szereday, L.; Polgar, B.; Balassa, T.; Kocsis, B.; Peterfi, Z.; Miko, E. Development of a New Serological Assay for the Diagnosis of Clostridium Difficile Infections with Prognostic Value. J. Microbiol. Methods 2019, 167, 105777.
  99. Crobach, M.J.T.; Planche, T.; Eckert, C.; Barbut, F.; Terveer, E.M.; Dekkers, O.M.; Wilcox, M.H.; Kuijper, E.J. European Society of Clinical Microbiology and Infectious Diseases: Update of the Diagnostic Guidance Document for Clostridium Difficile Infection. Clin. Microbiol. Infect. 2016, 22, S63–S81.
  100. Carmeli, Y.; Samore, M.H.; Huskins, W.C. The Association Between Antecedent Vancomycin Treatment and Hospital-Acquired Vancomycin-Resistant Enterococci: A Meta-Analysis. Arch. Intern. Med. 1999, 159, 2461–2468.
  101. Correa-Martínez, C.L.; Hagemeier, N.C.J.; Froböse, N.J.; Kampmeier, S. Impact of Clostridioides difficile Therapy on Nosocomial Acquisition of Vancomycin-Resistant Enterococci. Pharmaceuticals 2021, 14, 1066.
  102. Sokol, H.; Lalande, V.; Landman, C.; Bourrier, A.; Nion-Larmurier, I.; Rajca, S.; Kirchgesner, J.; Seksik, P.; Cosnes, J.; Barbut, F.; et al. Clostridium Difficile Infection in Acute Flares of Inflammatory Bowel Disease: A Prospective Study. Dig. Liver Dis. 2017, 49, 643–646.
  103. Goodhand, J.R.; Alazawi, W.; Rampton, D.S. Systematic Review: Clostridium Difficile and Inflammatory Bowel Disease: Systematic Review: Clostridium Difficile and IBD. Aliment. Pharmacol. Ther. 2011, 33, 428–441.
  104. Sinh, P.; Barrett, T.A.; Yun, L. Clostridium Difficile Infection and Inflammatory Bowel Disease: A Review. Gastroenterol. Res. Pract. 2011, 2011, 136064.
  105. Dalal, R.S.; RAllegretti, J.R. Diagnosis and Management of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease. Curr. Opin. Gastroenterol. 2021, 37, 336–343.
  106. Kirkpatrick, I.D.C.; Greenberg, H.M. Evaluating the CT Diagnosis of Clostridium Difficile Colitis: Should CT Guide Therapy? Am. J. Roentgenol. 2001, 176, 635–639.
  107. Kawamoto, S.; Horton, K.M.; Fishman, E.K. Pseudomembranous Colitis: Spectrum of Imaging Findings with Clinical and Pathologic Correlation. RadioGraphics 1999, 19, 887–897.
  108. Macari, M.; Balthazar, E.J.; Megibow, A.J. The Accordion Sign at CT: A Nonspecific Finding in Patients with Colonic Edema. Radiology 1999, 211, 743–746.
  109. Siddiqui, J.; Campion, T.; Wei, R.; Kuzmich, S. Clostridium Difficile Enteritis: Diffuse Small Bowel Radiological Changes in a Patient with Abdominal Sepsis. BMJ Case Rep. 2018, 2018, bcr-2017-222209.
  110. Nasser, H.; Munie, S.; Shakaroun, D.; Ivanics, T.; Nalamati, S.; Killu, K. Clostridium Difficile Enteritis after Total Abdominal Colectomy for Ulcerative Colitis. Case Rep. Crit. Care 2019, 2019, 2987682.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback